Sign in
CompletedNo phase

Effectiveness of Myopia Control Interventions : A Comparison of Myopia Control in European Children, Adolescents and Young Adults With Defocus Incorporated Multiple Segments (DIMS) and Highly Aspherical Lenslets (HAL) Spectacles, Atropine, Lenses and Combined Treatments

Key facts

Who runs it
Centre Hospitalier Universitaire de Saint Etienne
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
114 people enrolled
Started
20 Oct 2024
Ended
7 May 2025
Type of study
Observational, 3 groups
Treatments tested
  • Demographic data collection
  • Ophthalmological history
  • Ophthalmological data at each examination
  • Potential adverse events
Record updated
13 August 2025

Who can take part

Age
Up to 25 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Children or young adults with active myopia treated with ATROPINE 0.01% eye drops or myopia control glasses or contact lenses, and their various combinations
  • patient affiliated with a social security organization
  • agreement of both parents or the patient if adult

Who cannot take part

  • non compliance with treatment

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The prevalence of myopia and its complications has risen considerably in recent decades, particularly among children and teenagers. This trend is also spreading in Europe, driven by the increase in screen time and the intensive use of new technologies and social media, particularly among the younger generation.

Read full original descriptionShow less

Several treatment options are available today, including pharmacological treatments with atropine eye drops, as well as optical myopia control systems in the form of glasses or contact lenses.

These different treatments have been used in clinical practice at Saint-Étienne University Hospital since 2017 for atropine, and more recently with the development of optical myopia control systems and their combinations.

Little clinical data has been published to date on these different treatment combinations in the French population.

The investigators would therefore like to set up a database to publish their results and share their experience.

The 3 groups in the trial

  • Atropine 0.01%

    Children or young adults with active myopia treated with ATROPINE 0.01% eye drops.

    Treatment: Demographic data collection, Ophthalmological history, Ophthalmological data at each examination, and Potential adverse events

  • DIMS/HAL

    Children or young adults with active myopia treated with myopia control glasses.

    Treatment: Demographic data collection, Ophthalmological history, Ophthalmological data at each examination, and Potential adverse events

  • Various combined treatments

    Children or young adults with active myopia treated with ATROPINE 0.01% eye drops or myopia control glasses or contact lenses, and their various combinations.

    Treatment: Demographic data collection, Ophthalmological history, Ophthalmological data at each examination, and Potential adverse events

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
13 August 2025